Search

Author/Creator Koenecke, C.

1. 133 UNRELATED CORD BLOOD OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS RECEIVING A REDUCED INTENSITY CONDITIONING REGIMEN: AN EBMT STUDY. Issue 1 (April 2015)

Authors:
Robin, M.; Ruggeri, A.; Labopin, M.; Nierderwieser, D.; Tabrizi, R.; Sanz, G.; Bouhris, J.H.; Van Biezen, A.; Koenecke, C.; Blaise, D.; Tischer, J.; Craddock, C.; Maillard, N.; Mohty, M.; Russel, N.; Schetelig, J.; Finke, J.; Gluckman, E.; De Witte, T.; Rocha, V.
Journal:
Leukemia research
Issue:
Volume 39:Issue 1(2015:Jan.)
Page Start:
S68
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT. Issue 3 (3rd February 2015)

Authors:
Basak, G. W.; Wiktor‐Jedrzejczak, W.; Labopin, M.; Schoemans, H.; Ljungman, P.; Kobbe, G.; Beguin, Y.; Lang, P.; Koenecke, C.; Sykora, K. W.; te Boome, L.; van Biezen, A.; van der Werf, S.; Mohty, M.; de Witte, T.; Marsh, J.; Dreger, P.; Kröger, N.; Duarte, R.; Ruutu, T.
Journal:
American journal of transplantation
Issue:
Volume 15:Issue 3(2015:Mar.)
Page Start:
705
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION. (23rd June 2022)

Authors:
Basak, G.; Peczynski, C.; Koenecke, C.; Terwel, S.; Cabrerizo, Y.; Penack, O.; Moiseev, I.; Schoemans, H.; Fegueux, N.; Potter, V.; Zeerleder, S.; Yakoub-Agha, I.; Collin, M.; Schanz, U.; Dreger, P.; Blaise, D.; Besley, C.; Glass, B.; Mohty, M.; Chabannon, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1327
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY. (23rd June 2022)

Authors:
Suvannasankha, A.; Bahlis, N.; Trudel, S.; Weisel, K.; Koenecke, C.; Oriol, A.; Voorhees, P. M.; Alonso, A. A.; Callander, N. S.; Mateos Manteca, M. V.; Reddy, N.; Hakim, S.; Patel, N.; Williams, D.; Jewell, R. C.; Zhou, X.; Gupta, I.; Nooka, A. K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
830
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗